Dianthus Therapeutics (DNTH) Liabilities and Shareholders Equity (2017 - 2025)

Dianthus Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $530.9 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 41.95% year-over-year to $530.9 million; the TTM figure through Dec 2025 stood at $1.8 billion (up 20.5% YoY), while the FY2025 annual figure was $530.9 million, up 41.95% from the prior year.
• Liabilities and Shareholders Equity was $530.9 million for Q4 2025 at Dianthus Therapeutics, down from $577.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $577.4 million in Q3 2025 to a low of $78.6 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $258.7 million across 5 years, with a median of $200.3 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 57.07% in 2023, then soared 369.19% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $189.9 million in 2021, then tumbled by 56.24% to $83.1 million in 2022, then surged by 115.86% to $179.4 million in 2023, then jumped by 108.47% to $374.0 million in 2024, then surged by 41.95% to $530.9 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $530.9 million (Q4 2025), $577.4 million (Q3 2025), and $326.1 million (Q2 2025), per Business Quant data.